更新或不更新ESCMID生物膜感染诊断和治疗指南——这就是问题所在!ESGB董事会的意见

IF 5.9 Q1 MICROBIOLOGY
Niels Høiby , Claus Moser , Antonio Oliver , Craig Williams , Gordon Ramage , Elisa Borghi , Joana Azeredo , Maria Dolores Macia , for the ESGB board
{"title":"更新或不更新ESCMID生物膜感染诊断和治疗指南——这就是问题所在!ESGB董事会的意见","authors":"Niels Høiby ,&nbsp;Claus Moser ,&nbsp;Antonio Oliver ,&nbsp;Craig Williams ,&nbsp;Gordon Ramage ,&nbsp;Elisa Borghi ,&nbsp;Joana Azeredo ,&nbsp;Maria Dolores Macia ,&nbsp;for the ESGB board","doi":"10.1016/j.bioflm.2023.100135","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The work on the ESGB guidelines for diagnosis and treatment of biofilm infections began in 2012 and the result was published in 2014. The guidelines have been and still are frequently cited in the literature proving its usefulness for people working with biofilm infections. At the ESGB Biofilm conference in Mallorca 2022 (Eurobiofilms2022) the board of the ESGB decided to evaluate the 2014-guidelines and relevant publications since 2014 based on a lecture given at the Eurobiofilms2022.</p></div><div><h3>Guideline methods</h3><p>The Delphi method for working on production of guidelines and the current ESCMID rules for guidelines are presented. The criteria for evaluation of relevant literature are very strict and especially for treatment, most clinicians and regulatory authorities require convincing results from Level I (randomized controlled trials) publications to justify changes of treatments. The relevant new biofilm literature and the relevant biofilm presentations from the Eurobiofilms meetings and ECCMID conferences was used for evaluating the contemporary relevance of the ESGB 2014 guidelines.</p></div><div><h3>Diagnosis of biofilm infections</h3><p>Several infectious diseases have been recognized as biofilm infections since 2014, but the diagnostic methods and therapeutic strategies are still the same as recommended in the 2014 ESGB guidelines which are summarized in this opinion paper.</p></div><div><h3>Treatment of biofilm infections</h3><p>Some promising new <em>in vitro</em> and <em>in vivo</em> (animal experiments) observations and reports for therapy of biofilm infections are mentioned, but they still await clinical trials.</p></div><div><h3>Conclusion</h3><p>The interim opinion at the present time (2022) is therefore, that the guidelines do not need revision now, but there is a need for survey articles discussing new methods of diagnosis and treatment of biofilm infections in order - hopefully – to give inspiration to conduct clinical trials which may lead to progress in diagnosis and treatment of patients with biofilm infections.</p></div>","PeriodicalId":55844,"journal":{"name":"Biofilm","volume":null,"pages":null},"PeriodicalIF":5.9000,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"To update or not to update the ESCMID guidelines for the diagnosis and treatment of biofilm infections – That is the question! The opinion of the ESGB board\",\"authors\":\"Niels Høiby ,&nbsp;Claus Moser ,&nbsp;Antonio Oliver ,&nbsp;Craig Williams ,&nbsp;Gordon Ramage ,&nbsp;Elisa Borghi ,&nbsp;Joana Azeredo ,&nbsp;Maria Dolores Macia ,&nbsp;for the ESGB board\",\"doi\":\"10.1016/j.bioflm.2023.100135\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>The work on the ESGB guidelines for diagnosis and treatment of biofilm infections began in 2012 and the result was published in 2014. The guidelines have been and still are frequently cited in the literature proving its usefulness for people working with biofilm infections. At the ESGB Biofilm conference in Mallorca 2022 (Eurobiofilms2022) the board of the ESGB decided to evaluate the 2014-guidelines and relevant publications since 2014 based on a lecture given at the Eurobiofilms2022.</p></div><div><h3>Guideline methods</h3><p>The Delphi method for working on production of guidelines and the current ESCMID rules for guidelines are presented. The criteria for evaluation of relevant literature are very strict and especially for treatment, most clinicians and regulatory authorities require convincing results from Level I (randomized controlled trials) publications to justify changes of treatments. The relevant new biofilm literature and the relevant biofilm presentations from the Eurobiofilms meetings and ECCMID conferences was used for evaluating the contemporary relevance of the ESGB 2014 guidelines.</p></div><div><h3>Diagnosis of biofilm infections</h3><p>Several infectious diseases have been recognized as biofilm infections since 2014, but the diagnostic methods and therapeutic strategies are still the same as recommended in the 2014 ESGB guidelines which are summarized in this opinion paper.</p></div><div><h3>Treatment of biofilm infections</h3><p>Some promising new <em>in vitro</em> and <em>in vivo</em> (animal experiments) observations and reports for therapy of biofilm infections are mentioned, but they still await clinical trials.</p></div><div><h3>Conclusion</h3><p>The interim opinion at the present time (2022) is therefore, that the guidelines do not need revision now, but there is a need for survey articles discussing new methods of diagnosis and treatment of biofilm infections in order - hopefully – to give inspiration to conduct clinical trials which may lead to progress in diagnosis and treatment of patients with biofilm infections.</p></div>\",\"PeriodicalId\":55844,\"journal\":{\"name\":\"Biofilm\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":5.9000,\"publicationDate\":\"2023-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biofilm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590207523000321\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biofilm","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590207523000321","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

背景ESGB生物膜感染诊断和治疗指南的工作始于2012年,结果于2014年公布。文献中经常引用该指南,证明其对生物膜感染患者有用。在2022年马略卡岛ESGB生物膜会议(Eurobiofilm2022)上,ESGB董事会决定根据在Eurobiofils2022上发表的演讲,评估2014年指南和自2014年以来的相关出版物。指南方法介绍了制定指南的德尔菲方法和当前的ESCMID指南规则。相关文献的评估标准非常严格,尤其是在治疗方面,大多数临床医生和监管机构需要I级(随机对照试验)出版物的令人信服的结果来证明治疗方法的改变是合理的。欧洲生物膜会议和ECCMID会议的相关新生物膜文献和相关生物膜演示用于评估ESGB 2014指南的当代相关性。生物膜感染的诊断自2014年以来,几种传染病已被认定为生物膜感染,但诊断方法和治疗策略仍与本意见书中总结的2014年ESGB指南中建议的相同。生物膜感染的治疗提到了一些有前景的新的体外和体内(动物实验)生物膜感染治疗观察和报告,但它们仍有待临床试验。结论因此,目前(2022年)的临时意见是,指南现在不需要修订,但有必要发表调查文章,讨论生物膜感染的诊断和治疗新方法,以便——希望——为开展临床试验提供启发,从而在生物膜感染患者的诊断和处理方面取得进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
To update or not to update the ESCMID guidelines for the diagnosis and treatment of biofilm infections – That is the question! The opinion of the ESGB board

Background

The work on the ESGB guidelines for diagnosis and treatment of biofilm infections began in 2012 and the result was published in 2014. The guidelines have been and still are frequently cited in the literature proving its usefulness for people working with biofilm infections. At the ESGB Biofilm conference in Mallorca 2022 (Eurobiofilms2022) the board of the ESGB decided to evaluate the 2014-guidelines and relevant publications since 2014 based on a lecture given at the Eurobiofilms2022.

Guideline methods

The Delphi method for working on production of guidelines and the current ESCMID rules for guidelines are presented. The criteria for evaluation of relevant literature are very strict and especially for treatment, most clinicians and regulatory authorities require convincing results from Level I (randomized controlled trials) publications to justify changes of treatments. The relevant new biofilm literature and the relevant biofilm presentations from the Eurobiofilms meetings and ECCMID conferences was used for evaluating the contemporary relevance of the ESGB 2014 guidelines.

Diagnosis of biofilm infections

Several infectious diseases have been recognized as biofilm infections since 2014, but the diagnostic methods and therapeutic strategies are still the same as recommended in the 2014 ESGB guidelines which are summarized in this opinion paper.

Treatment of biofilm infections

Some promising new in vitro and in vivo (animal experiments) observations and reports for therapy of biofilm infections are mentioned, but they still await clinical trials.

Conclusion

The interim opinion at the present time (2022) is therefore, that the guidelines do not need revision now, but there is a need for survey articles discussing new methods of diagnosis and treatment of biofilm infections in order - hopefully – to give inspiration to conduct clinical trials which may lead to progress in diagnosis and treatment of patients with biofilm infections.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Biofilm
Biofilm MICROBIOLOGY-
CiteScore
7.50
自引率
1.50%
发文量
30
审稿时长
57 days
期刊介绍:
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信